Shares of Sarepta Therapeutics (NASDAQ: SRPT) experienced a significant surge on Thursday, climbing 12.9% to $21.98 and approaching the day's high of $22.57. Trading volume was notably elevated, with approximately 5.94 million shares changing hands, nearly double the recent average of 3.2 million. This rally added roughly $265 million to the company's market capitalization, bringing it to about $2.32 billion.
The catalyst for this move appears to be a procedural update to the ClinicalTrials.gov record for the ENHANCE study (NCT07542314), a Phase 4 safety trial evaluating Elevidys in combination with prophylactic sirolimus. The update, posted on August 26 and visible on August 27, added Baylor College of Medicine as a new trial site. While this expands the trial's operational footprint, the timeline has been pushed back: the estimated start date slipped from July 31, 2026, to August 31, 2026, and the primary and final completion dates have been delayed by five months, from March 31, 2027, to August 31, 2027.
The ENHANCE study is critical for Sarepta's regulatory strategy. It aims to measure acute liver injury during the first 12 weeks after Elevidys treatment when sirolimus is added to the immunosuppressive regimen. In its latest Form 10-Q, Sarepta stated that any path to resuming commercial dosing in non-ambulatory Duchenne muscular dystrophy patients depends on the FDA's assessment of whether the sirolimus data improves Elevidys' risk-benefit profile and on agreement over a label revision.
Thursday's registry change is not a positive clinical readout, nor an FDA decision, nor the start of patient recruitment. Sarepta's investor relations page showed no new press releases since August 5, and there was no disclosed acquisition agreement to justify takeover speculation. So why did the stock jump? The answer may lie in market positioning.
Recent short-interest data revealed that approximately 27.05 million shares were sold short, representing about 27% of the public float and 9.1 days of average trading volume. A heavily shorted stock can experience rapid rallies when momentum traders jump in, but this also heightens the risk of a sharp reversal if sentiment shifts.
The fundamental backdrop remains challenging. In the second quarter, Sarepta reported total revenue of $401.3 million, a 34% decline year-over-year. Net product revenue fell 36% to $328.7 million, with Elevidys revenue dropping 65% to $98.1 million. The older PMO portfolio was nearly flat at $230.6 million. The company holds $945.0 million in cash, investments, and restricted cash, against $847.6 million in debt. Inventory stands at $1.13 billion, including an $11.6 million obsolescence write-down, and non-cancelable manufacturing commitments total $428.0 million.
Given these financial pressures, the success of Elevidys and potential label expansion are not just clinical milestones but financial necessities. The bull case argues that the Baylor addition helps ENHANCE activate, sirolimus data could eventually support a broader label, and high short interest may extend the rally. The base case treats the registry edit as procedural, with the stock consolidating while awaiting recruitment and second-half data for DM1 and FSHD programs. The bear case highlights the five-month completion delay, boxed-warning risk, and weak Elevidys sales, which could cause the squeeze to fade.
Investors should watch for verifiable signals: a change in recruitment status, the first-patient milestone, any FDA update on the non-ambulatory pathway, and new company guidance on Elevidys demand. Until then, Thursday's 13% gain appears more driven by expectations and positioning than by new clinical evidence.
